Impax Laboratories, LLC

2 marketed · 5 in Phase 3

Quick facts

Founded	1995

CLE · Neurology
CLE is a combination formulation of carbidopa and levodopa in an extended-release delivery system designed to provide more consistent dopamine replacement in the brain for Parkinson's disease management.
CREXONT ER · Infectious Disease
CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

IPX066 · Neurology
IPX066 is an extended-release formulation of levodopa and carbidopa designed to provide more consistent dopamine replacement in the brain over an extended period.
IPX203 · Pain Management
IPX203 is an extended-release combination of morphine and naltrexone designed to provide opioid analgesia while reducing the potential for abuse and addiction.
IPX203 ER CD-LD · Neurology
IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.
IR CD-LD · Neurology
IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control.
Placebo ZNS · Neurology
Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade.

Baclofen IR · Neurology
Baclofen IR is a central nervous system depressant that acts as a GABA_B receptor agonist.
CD-LD CR · Attention Deficit Hyperactivity Disorder (ADHD)
CD-LD CR is a controlled-release formulation of a central nervous system stimulant.
CD-LD IR · Psychiatry
CD-LD IR is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD).
IPX056
IPX159
Extended-release formulation of carbidopa-levodopa that provides sustained dopamine replacement in the brain for Parkinson's disease treatment.

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Top marketed products include CLE, CREXONT ER.

Impax Laboratories, LLC has 5 drugs in Phase 3, 5 in Phase 2, 2 in Phase 1. Late-stage candidates include IPX066, IPX203, IPX203 ER CD-LD, IR CD-LD.

Impax Laboratories, LLC was founded in 1995.